DE820142C - Process for the preparation of a salt of heparic acid - Google Patents

Process for the preparation of a salt of heparic acid

Info

Publication number
DE820142C
DE820142C DEH5139A DEH0005139A DE820142C DE 820142 C DE820142 C DE 820142C DE H5139 A DEH5139 A DE H5139A DE H0005139 A DEH0005139 A DE H0005139A DE 820142 C DE820142 C DE 820142C
Authority
DE
Germany
Prior art keywords
salt
acid
preparation
solution
ephedrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DEH5139A
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE820142C publication Critical patent/DE820142C/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Description

Verfahren zur Herstellung eines Salzes der Heparinsäure Zur Verhinderung von Thrombosen werden sowohl blutzirkulationsanregende als auch blutgerinnungshemmende Mittel verwendet. Unter den Mitteln zur Stützung des Kreislaufes hat sich F-pliedrin bew#ihrt. Als blutgerinnungshemmender Stoff dient heute vorzugsv,-eise das lleparin, ein Es \\-tir(I(, nun gefunden, daß das Ephedrinsalz der Heparinsäure sowohl eine die Blutzirkulation anregende, als auch eine blutgerinnungshemmende Wirkung aufweist. Zur lIerstellung dieses Salzes wird die Ileparinsäure auf Ephedrin in Gegenwart eines geeigneten Lösungsmittels, beispielsweise wässerIger ,#thvl,-illohol, einwirken gelassen. Durch Eindampfen der entstandenen Salzlösung werden mehr oder weniger feinkörnige Pulver erhalten. Die Heparinsäure läßt sich aus dem Natriumsalz durch Behandlung mit einem geeigneten Kationenaustauscher gewinnen.Process for the preparation of a salt of heparic acid Both blood circulation-stimulating and anti-coagulant agents are used to prevent thrombosis. F-pliedrin has proven himself among the means to support the circulation. , Now found tir (I (that the ephedrine salt of heparin acid both blood circulation stimulating, and has an anticoagulant effect to lIerstellung this salt is the Ileparinsäure - today as anticlotting substance used vorzugsv, -eise the lleparin a time \\. left to act on ephedrine in the presence of a suitable solvent, for example aqueous, # thvl, -illohol. More or less fine-grained powders are obtained by evaporation of the resulting salt solution. The heparic acid can be obtained from the sodium salt by treatment with a suitable cation exchanger.

Bei intravenöser Verabreichung des neuen Salzes beobachtet man neben der starken blutgerinnungshemmenden Wirkung des ileparins gleichzeitig eine Verbesserung der Blutzirkulatiorn. Bei intramuskulärer Zufuhr sind diese beiden Effekte ebenfalls festzustellen. Infolge der kapillarverengenden Wirkung der basischen Komponente tritt bei intramuskulärer Einspritzung des Ephedrinsalzes eine protrahierte Heparinwirkung auf.When the new salt is administered intravenously, one observes next to the strong anticoagulant effect of the ileparin at the same time an improvement the blood circulation. When given intramuscularly, these two effects are also present ascertain. As a result of the capillary-narrowing effect of the basic component If the ephedrine salt is injected intramuscularly, a protracted heparin effect occurs on.

B e i s p i e 1 i GewIchtsteil Heparin wird in 2o Gewichtsteilen Wasser gelöst und die Lösung durch eine mit 2oGewichtsteilen eines mit Salzsäure' behandelten sauren Kationenaustatischers fließen gelassen.EXAMPLE 1 part by weight of heparin is dissolved in 20 parts by weight of water and the solution is allowed to flow through an acidic cation static eliminator treated with hydrochloric acid.

Man wäscht zweimal mit iooGewichtsteilen Wasser nach und versetzt die erhaltene wässerige Heparinsäurelösung mit einer Lösung von 1,5 Gewichtsteilen Ephedrinbase in 20 (3ewichtsteilen Äthylalkohol.It is washed twice with 100 parts by weight of water and the aqueous heparic acid solution obtained is mixed with a solution of 1.5 parts by weight of ephedrine base in 20 (3 parts by weight of ethyl alcohol.

Nun wird im Vakuum zur Trockne eingedampft und die überschüssige Ephedrinbase durch Auswaschen des Rückstandes mit Aceton und Äther entfernt. Nach achtstündigem Trocknen im Vakuum bei 8o' C erhält man i"# Gewichtsteile des 1,--pliedrinsalzes der Heparinsäure. Die neue Verbindung enthält 51,5 % Ephedrin und ist leicht löslich in Wasser, schwer löslich in organischen Lösungsrnitteln. Die Stimmeilforrnel des Salzes ist die folgende: C 14 H21 020 IN S 3 - (CIO"150'N)4 Heparinsäure Ephedrin.It is now evaporated to dryness in vacuo and the excess ephedrine base is removed by washing out the residue with acetone and ether. After eight hours of drying in vacuo at 80 ° C. one receives i "# parts by weight of the 1, - pliedine salt of heparic acid. The new compound contains 51.5% ephedrine and is easily soluble in water, sparingly soluble in organic solvents is the following: C 14 H21 020 IN S 3 - (CIO "150'N) 4 heparic acid ephedrine.

Claims (2)

P ATE NTANS PP, ü CHE: i, Verfahren zur Herstellung eines Salzes der Heparinsätire, dadurch gekennzeichnet, daß 1-lel)arinsäureaufEl)lie(Ii-iii inGegenNvart eines geeigneten Lösungsmittels einwirken gelassen wird. P ATE NTANS PP, ü CHE: i, process for the preparation of a salt of the heparin sateire, characterized in that 1-lel) arinic acid is allowed to act on el) lie (ii-iii in the presence of a suitable solvent. 2. Verfahren gemiß Anspruch 1, dadurch gekennzeichnet, (laß eine -,#-:is.serige Lösung der Ileparinsäure mit einer i*-itli#'lalloholischen Lösung des Ephedrins veriniscilt und das entstandetie Salz der Heparinsäure durch Eindampfen der Lösung gewonnen wird.2. The method according to claim 1, characterized in that (let a -, # -: is.serige solution of ileparic acid with an i * -itli # 'lalloholischen solution of ephedrine veriniscilt and the resulting salt of heparic acid is obtained by evaporation of the solution.
DEH5139A 1949-09-14 1950-08-31 Process for the preparation of a salt of heparic acid Expired DE820142C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA820142X 1949-09-14

Publications (1)

Publication Number Publication Date
DE820142C true DE820142C (en) 1951-12-03

Family

ID=4172580

Family Applications (1)

Application Number Title Priority Date Filing Date
DEH5139A Expired DE820142C (en) 1949-09-14 1950-08-31 Process for the preparation of a salt of heparic acid

Country Status (1)

Country Link
DE (1) DE820142C (en)

Similar Documents

Publication Publication Date Title
DE820142C (en) Process for the preparation of a salt of heparic acid
DE1055544B (en) Process for the preparation of derivatives of 7-oxyflavone
DE493025C (en) Process for the preparation of o-arylaminorhodane compounds
DE839802C (en) Process for the preparation of salts of heparic acid
DE949471C (en) Process for the production of new esters of yohimbine
DE1041038B (en) Process for the production of low-toxicity salts of basic Streptomyces antibiotics
DE543529C (en) Process for the preparation of optically active monooxyphenylalkamines
DEH0005139MA (en) Process for the preparation of a salt of heparic acid
CH286276A (en) Process for the preparation of a salt of heparic acid.
DE685144C (en) Process for the preparation of physiologically active substances from the adrenal glands
DE960194C (en) Process for the preparation of an undecylenic acid ester which is therapeutically effective against mycosis
AT216669B (en) Process for the preparation of compounds from penicillin and sulfamides
DE2147263C3 (en)
DE963514C (en) Process for the production of poorly soluble, crystallized streptomycin and dihydrostreptomycin salts
DE876441C (en) Process for the production of a knitted body from hawthorn
DE716089C (en) Process for the preparation of new derivatives of p-aminobenzenesulfonamide
DE869137C (en) Pest control
DE910167C (en) Process for the production of a bismuth salt of penicillin
DE2027832C3 (en) Process for the production of thiamphenicol glycinate acetylcysteinate
AT67205B (en) Process for the production of a mercury preparation, in particular for therapeutic purposes.
DE889896C (en) Process for the production of mono- or di-ethanol-amine hydrorhodanide
DE1643652C (en) 3, 4 diathers of helveticoside and process for their preparation
DE527715C (en) Process for the preparation of easily soluble salts of 3-acetylamino-4-oxybenzene-1-arsic acid
CH493549A (en) Hypertensive basic diphenyl ether deriv
DE1149859B (en) Bactericidal, fungicidal and insecticidal agents